Poster

• Achievement of Minimal Symptom Expression in Participants Treated With Efgartigimod in ADAPT+ and ADAPT-SC+
• COVID-19 Vaccination Response in Participants Receiving Efgartigimod IV or Efgartigimod PH20 SC in ADAPT+ or ADAPT-SC+
• Efficacy and Safety of Efgartigimod IV and PH20 SC in gMG: Analysis of AChR-Ab− Participants in ADAPT+/ADAPT-SC+
• Efgartigimod Consistently Improved Health-Related Quality of Life in AChR-Ab+ Participants With gMG in IV and SC Trials
• Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalised Myasthenia Gravis: Part A of ADAPT NXT
• Long-Term Safety and Efficacy of Subcutaneous Efgartigimod PH20: Interim Results of the ADAPT-SC+ Trial
• Real world reduction in oral corticosteroid utilization following efgartigimod initiation
• Safety Profile of Intravenous Efgartigimod From Clinical Trials in Immunoglobulin G–Mediated Autoimmune Diseases
• Steroid toxicity in adults with myasthenia gravis in the United States based on electronic health records
• Subcutaneous Efgartigimod PH20 Demonstrates Improvements in gMG Patients Regardless of Prior Administration Route

Poster

• Achievement of Minimal Symptom Expression in Acetylcholine Receptor Antibody-Positive Participants Treated With Efgartigimod in ADAPT/ADAPT+
• Real-World Reduction in Oral Corticosteroid Utilization Following Efgartigimod Initiation in Patients With Generalized Myasthenia Gravis

Poster

• Changes in Nonsteroidal Immunosuppressive Treatment Usage Before and After Efgartigimod Initiation in Patients With Myasthenia Gravis
• Combined Analyses of Participants With Anti-Acetylcholine Receptor Seronegative Generalized Myasthenia Gravis Treated With Efgartigimod Across Clinical Studies
• COVID-19 Vaccination Response in Participants Across Clinical Trials Investigating Efgartigimod in Autoimmune Diseases
• Design of a Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults With Ocular Myasthenia Gravis
• First-in-Human Dose Selection and Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ARGX-119, an Agonist Antibody for Human Muscle-Specific Kinase
• Hospitalization Outcomes After Efgartigimod Initiation in Patients With Myasthenia Gravis
• Investigating the Pharmacokinetics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administration Using a Prefilled Syringe
• Long-Term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants With Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study
• Network Meta-Analysis of Treatment Options in Generalized Myasthenia Gravis: Evaluating the Comparative Effectiveness of Emerging Immunomodulatory Therapies
• Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody-Negative Generalized Myasthenia Gravis
• Study Design of Subcutaneous Efgartigimod PH20 in Juvenile Generalized Myasthenia Gravis
• Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT
• Transition From Intravenous Immunoglobulin to Efgartigimod PH20 SC in Participants With Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 4 Study in Progress
• Treatment Impact of Efgartigimod PH20 SC on I-RODS Daily Activity Assessment in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: Post Hoc Analysis of the Registrational ADHERE Study

Poster

• Employment, daily activities and caregiver burden in CIDP: results of a real-world US survey
• Incremental economic and clinical burden of illness among adults with chronic inflammatory demyelinating polyneuropathy in the United States
• Magnitude of Response With Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy ADHERE_ADHERE+ Trials
• Study Design of Subcutaneous Efgartigimod PH20 in Juvenile Generalized Myasthenia Gravis

Poster

• Clinical Outcomes, Disease Course, and Health-Related Quality of Life in PatientsWith Multifocal Motor Neuropathy: iMMersioN, Study in Progress

• ADHERE+ Trial Interim Analysis: Long-Term Safety and Efficacy of Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy
• Autoantibody Signatures in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Insights on Glycolipid Reactivity From the ADHERE Trial
• Baseline Characteristics of the First 100 Study Participants with Multifocal Motor Neuropathy in the iMMersioN study
• Burden of Disease in Multifocal Motor Neuropathy: A Global Quantitative Survey of Patients
• Efgartigimod in Pretreated CIDP With Persistent Disease Activity or Progressive-Relapsing Active Disease: ADHERE Analysis
• Empasiprubart in Multifocal Motor Neuropathy: Safety and Efficacy Data From the Phase 2 ARDA Study
• Empasiprubart Versus Intravenous Immunoglobulin in Multifocal Motor Neuropathy Phase 3 Study Design: EMPASSION
• Impact of Efgartigimod PH20 SC on Autoimmunity Biomarkers in the ADHERE Trial: Exploratory Analyses
• Impact of Prior Chronic Inflammatory Demyelinating Polyneuropathy Treatments in the ADHERE Trial Post Hoc Analyses
• Intravenous Immunoglobulin to Efgartigimod in Chronic Inflammatory Demyelinating Polyneuropathy: A Phase 4 Study in Progress
• Management of Patients With Multifocal Motor Neuropathy: A Global Quantitative Survey of Neurologists

Poster

• Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy: Results of ADHERE/ADHERE+
• Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis

Poster

• Clinical Outcomes Disease Course and QoL in Patients With Multifocal Motor Neuropathy iMMersioN Study in Progress
• Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Chronic Inflammatory Demyelinating Polyneuropathy Results of ADHEREADHERE+
• Empasiprubart (ARGX-117) in Multifocal Motor Neuropathy_Initial Safety and Efficacy Data of the Phase 2 ARDA Study
• Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis_Part A of ADAPT NXT
• Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
• Tapering of Corticosteroids in Patients With Generalized Myasthenia Gravis Treated With Efgartigimod A Case Series

• Comparative Risk-Benefit Profiles of Immunomodulatory Therapies for Patients with Generalized Myasthenia Gravis
• Design of a Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Adm
• Efficacy, Safety, and Pharmacodynamics of Efgartigimod PH20 SC Across Bodyweight Quartiles A Post hoc Analysis of the ADAPT-SC+ Trial
• Exploring the Impact of Nonsteroidal Immunosuppressive Drugs and Steroids on the Development of Comorbidities in Patients With Myasthenia Gravis
• Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT
• Observed Efficacy of Efgartigimod in Generalized Myasthenia Gravis Across Patient Subgroups in the ADAPT-SC+ Study
• Patterns Of Efgartigimod Dosing In Clinical Practice In The United States
• Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
• Quality Of Life of Patients with Symptomatic Ocular MG Comparison with the General Population
• Real-World Reduction in Oral Glucocorticoid Utilization at 1-Year Following Efgartigimod Initiation
• Steroid Use, Toxicity, and Monitoring in Patients With Generalized Myasthenia Gravis A Survey of Neurologists in the United States

Poster

• Clinical Outcomes, Disease Course, and Quality of Life in Patients With MultifocalMotor Neuropathy iMMersioN, Study in Progress
• Combined Analyses of Participants With Anti-Acetylcholine Receptor Seronegative Generalized Myasthenia Gravis Treated With Efgartigimod Across Clinical Studies
• COVID-19 Vaccination Response in Participants Receiving Efgartigimod IV or Efgartigimod PH20 SC in ADAPT+ or ADAPT-SC+
• Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy ADHERE Trial Subgroup Analysis
• Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy ADHEREADHERE+ Trials
• Empasiprubart (ARGX-117) in Multifocal Motor Neuropathy Initial Safety and Efficacy Data of the Phase 2 ARDA Study
• Empasiprubart(ARGX-117) in Multifocal Motor Neuropathy Baseline Characteristics and MMN Confirmation Committee Outcomes of the Phase 2 ARDA Stud
• Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part A of ADAPT NXT
• Heterogeneity of EQ-5D-5L utilities among people suffering from CIDP
• Long-Term Safety and Efficacy of Efgartigimod PH20 SC in Generalized Myasthenia Gravis Interim Analysis of Anti-Acetylcholine Receptor Antibody
• Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Participants With Generalized Myasthenia Gravis Interim Result
• Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
• Real-World Reduction in Oral Glucocorticoid Utilization at 1-Year Following Efgartigimod Initiation
• Risk of Serious Infections and Malignancies in Adult Myasthenia Gravis Patients A US Claims Database Study
• Safety Profile of Intravenous Efgartigimod From Clinical Trials in Immunoglobulin G-Mediated Autoimmune Diseases
• Safety Profile of Subcutaneous Efgartigimod PH20 From Clinical Trials in Immunoglobulin G-Mediated Autoimmune Diseases
• Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of ARGX-119 in Patients With Amyotrophic Lateral Sclerosis A Phase 2a Study
• Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Participants With DOK7 Congenital Myasthenic Syndromes Phase
• Steroid Toxicity in Adults With Myasthenia Gravis in the United States Based on Electronic Health Records
• Steroid Use, Toxicity, and Monitoring in Patients With Chronic Inflammatory Demyelinating Polyneuropathy A Survey of Neurologists in the United
• Steroid Use, Toxicity, and Monitoring in Patients With Generalized Myasthenia Gravis A Survey of Neurologists in the United States
• Subcutaneous Efgartigimod PH20 in Chronic Inflammatory Demyelinating Polyneuropathy Key Secondary Outcomes From the ADHERE Trial
• The Burden people suffering from CIDP experience In terms of Utilities Comparison With The General Population

• Assessing Efgartigimod Dosing Patterns and Myasthenia Gravis Activities of Daily Living Outcomes in Clinical Practice: Results from a Large Patient Support Program Database in the United States
• Combined Analyses of Participants Treated With Efgartigimod Early in the Course of Generalized Myasthenia Gravis Across Clinical Studies
• Combined Analyses of Participants With Anti-Acetylcholine Receptor Seronegative Generalized Myasthenia Gravis Treated With Efgartigimod Across Clinical Studies
• COVID-19 Vaccination Response in Participants Across Clinical Trials Investigating Efgartigimod in Autoimmune Diseases
• Design of a Phase 3 Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Subcutaneous Efgartigimod PH20 Administered by Prefilled Syringe in Adults With Ocular Myasthenia Gravis
• Effect of Intravenous and Subcutaneous Efgartigimod on MG-ADL and QMG Subdomains in the ADAPT-SC Study in Participants With Generalized Myasthenia Gravis
• First-in-Human Dose Selection and Pharmacokinetics, Safety, Tolerability, and Immunogenicity of ARGX-119, an Agonist Antibody for Human Muscle-Specific Kinase
• Investigating the Pharmacokinetics, Injection Speed, and Usability of Subcutaneous Efgartigimod PH20 Administration Using a Prefilled Syringe
• Long-Term Safety and Efficacy of Subcutaneous Efgartigimod PH20 in Adult Participants With Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study
• Network Meta-Analysis of Treatment Options in Generalized Myasthenia Gravis: Evaluating the Comparative Effectiveness of Emerging Immunomodulatory Therapies
• Observed Efficacy of Efgartigimod in Generalized Myasthenia Gravis Across Patient Subgroups in the ADAPT-SC+ Study
• Phase 3 Trial Investigating Impact of Intravenous Efgartigimod in Anti-Acetylcholine Receptor Antibody Negative Generalized Myasthenia Gravis
• Real-World Reduction in Oral Corticosteroid Utilization at 1-Year Following Efgartigimod Initiation
• Structure-function analysis of ARGX-119, a first-in-class humanized agonist monoclonal antibody specific for muscle-specific kinase
• Study Design of Subcutaneous Efgartigimod PH20 in Juvenile Generalized Myasthenia Gravis
• Sustained Clinical Efficacy and Long-Term Safety of Intravenous Efgartigimod for Generalized Myasthenia Gravis Part B of ADAPT NXT